Determination of dosimetric characteristics of a new design 125I brachytherapy source with marker of Ag+Al2O3 using the monte carlo code MCNPX

Authors

10.22052/1.4.11

Abstract

The purpose of this study is to determine the dosimetric parameters of a new 125I brachytherapy seed model, using Monte Carlo (MC) simulations according to the TG-43U1 recommendation. The Monte Carlo simulated dosimetric parameters of this sourse have been provided with MCNPX v.2.6 code. The source contains a cylindrical Ag+Al2O3 marker which is located at the center of the seed and onto which a thin layer of 125I has been uniformly adsorbed. The results of this evaluation indicate the value of the dose rate constant of 0.980 ± 0.12 cGyh−1U−1 in liquid water. The parameters of this source were determined and compared with other commercial sources models and there was an acceptable agreement between calculated dosimetric parameters of this new source and other commercial sources models and it indicates that this seed is an acceptable seed for clinical use.

Keywords


[1] D. Nori, Conformal brachytherapy of prostate cancer: an effective outpatient treatment. Cancer Watch 1 (1992), 124–126. [2] K.J. Russell and J.C. Blasko, Recent advances in interstitial brachytherapy for localized prostate cancer. Probl. Urol. 7 2 (1993), 260–278. [3] M.S. Porrazzo, B.S. Hilaris, C.R. Moorthy, A.E. Tchelebi, C.A. Mastoras, L.L. Shih, L. Stabile and N. Salvaras, Permanent interstitial implantation using palladium-103: The New York Medical college preliminary experience. Int. J. Rad. Onc. Biol. Phys. 23 (1992), 1033–1036. [4] J.C. Blasko, K. Wallner, P.D. Grimm and H. Ragde, Prostate specific antigen based control following ultrasound guided 125I implantation for Stage T1/T2 Prostate carcinoma. J. Urol. 154 (1995), 1096–1099. [5] Duggan DM, Improved radial dose function estimation using current version MCNP Mont-Carlo simulation: Model 6711 and ISC3500 125I brachytherapy sources, Appli Radiat Isot. 61 (2004),1443-1450. [6] Usgaonker SR, MCNP Modeling of prostate brachytherapy and of organ dosimetry, 2003; MSc thesis, USA. [7] U. J. Park, J. S Lee, K. J. Son, H. S. Han, S. S. Nam, The adsorption of 125I on a Ag+Al2O3 rod as a carrier body for a brachytherapy source. Journal of Radioanalytical and Nuclear Chemistry. 277 2 (2008), 429–432. [8] M.J. Rivard, B.M. Coursey, L.A. DeWerd, W.F. Hanson, M.S. Huq, G.S. Ibbott, M.G. Mitch, R. Nath and J.F. Williamson, Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations, Med. Phys. 31 (2004), 633–674. [9] R. Nath and N. Yue, Dosimetric characterization of a newly designed encapsulated interstitial brachytherapy source of iodine-125—model LS-1 BrachyseedTM, Appl. Radiat. Isot. 55 (2001), 813–821. [10] J.F. Briesmeister, Editor, MCNP-4C A General Monte Carlo N-Particle Transport Code System—Version 4C, Los Alamos National Laboratory, Louisiana (2000). [11] M. Sadeghi, G. Raisali, S.H. Hosseini and A. Shavar, Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA 103Pd brachytherapy source, Med. Phys. 34 (2008), 1288–1294. [12] Z. Li, J.R. Palta and J.J. Fan, Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source, Med. Phys. 27 (2000), pp. 1108–1112. [13] M.J. Rivard, A discredited approach to determining TG-43 brachytherapy dosimetry parameters: case study using Monte Carlo calculation for the 103Pd MED3633 source, Appl. Radiat. Isot. 55 (2001), 775–782. [14] Z. Li, J.R. Palta and J.J. Fan, Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source, Med. Phys. 27 (2000), 1108–1112. [15] A.S. Meigooni, Z. Bharucha, M. Yoe-Sein and K. Sowards, Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source, Med. Phys. 28 (2001), 2568–2575. [16] Ali S. Meigooni,a) Joshua L. Hayes, Hualin Zhang, and Keith Sowards, Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE™125I brachytherapy source, Med. Phys. 29 9 (2002), 2152–2158. [17] J. F. Williamson, H. Perera, and Z. Li, Comparison of calculated and measured hetrogeneity correction factors for 125I, 137Cs, and 192Ir brachytherapy source near localized hetrogeneities, Med. Phys. 20 (1993), 209–222. [18] A. S. Meigooni, M. M. Yoe-Sein, A. Al-Otoom, and K. Sowards, Determination of the dosimetric characteristics of interSource125 iodine brachytherapy source, Appl. Radiat. Isot. 56 (2002), 589–599. [19] A.S. Meigooni, D.G. Gearheart and K. Sowards, Experimental determination of dosimetric characteristics of Best® 125I brachytherapy source, Med. Phys. 27 9 (2000), 2168–2173. [20] R.E. Wallace and J.J. Fan, Report on the dosimetry of a new design 125I brachytherapy source. Med. Phys. 26 9 (1999), 1925–1931.